Skip to main content

Peer Review reports

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Original Submission
28 Dec 2020 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
13 Feb 2021 Reviewed Reviewer Report
27 Apr 2021 Reviewed Reviewer Report - Hans-christian Kolberg
17 May 2021 Author responded Author comments - Jieqiong Liu
Resubmission - Version 3
17 May 2021 Submitted Manuscript version 3
24 May 2021 Reviewed Reviewer Report - Hans-christian Kolberg
11 Jun 2021 Reviewed Reviewer Report
19 Jun 2021 Author responded Author comments - Jieqiong Liu
Resubmission - Version 4
19 Jun 2021 Submitted Manuscript version 4
Publishing
16 Jul 2021 Editorially accepted
27 Jul 2021 Article published 10.1186/s12885-021-08612-y

You can find further information about peer review here.

Back to article page